Vaccination Liberation - Information
Legal: Science: Misc: Searches:

Package Inserts
Ingredients of Vaccines
Artificially Sweetened Times
Books Videos Tapes
100+ Anti-Vax links
Breaking News
Smallpox Alert!

CRP levels after vaccination
[multiple simultaneous versus single vaccinations.]
Evidence of serious health consequences was recently confirmed in the Journal of Pediatrics in which CRP levels were measured after vaccination. CRP, short for C-reactive protein, is a blood marker indicating a heightened state of inflammation throughout the body.

The study involved infants in a neonatal intensive care unit who were given two or more vaccines on the same day. A separate group of infants were given one shot at a time, every three days. The vaccines administered were DTaP, Hib, polio [IPV], hepatitis B and Prevnar. The findings were disturbing:

· An abnormally elevated CRP occurred in 85 percent of infants who received simultaneous vaccines and nearly 70 percent of infants who received the shots one at a time.

· Gastroesophageal reflux (GERD) and severe intraventricular hemorrhage (bleeding in the brain) also occurred in infants who received multiple vaccines at the same time.

· Cardiorespiratory events (stopped breathing) occurred in 16 percent of all infants within 48 hours after receiving the vaccines.

· Infants who received DTaP, Prevnar and Hib as single injections experienced the largest number of cardiorespiratory events overall.

REF: Pourcyrous, M., et al. Primary Immunization of Premature Infants with Gestational Age 35 Weeks. J of Pediatrics, Vol. 51, Issue 2, Pages 167-172. August, 2007.

There are further concerns about elevated CRP levels. It was found in a study of 62 children who were part of the Diabetes Autoimmunity Study that when infants and young children have an elevated CRP level, they have an increased risk of developing Type 1 (insulin-dependent) diabetes in childhood. REF: Chase HP, et al. Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes. 2004 Oct;53(10):2569-73.


But vaccines are BIG business! There is marketplace growth for these products maiming and killing our children -

See next article for projected increase in vaccine sales.


Booster Shot
[Vaccine sales projected to rise]

A new golden age of vaccines is at hand, promising inoculations against malaria, meningitis and much more.

Vaccine researcher Ripley Ballou was an eager human guinea pig. As part of a six-man experiment at the Walter Reed Army Institute of Research in 1987, he had himself injected four times with a genetically engineered malaria vaccine. Then he taped to his arm a styrofoam cup. In it were five mosquitoes infected with malaria.

Ten days later Ballou got violently ill, with uncontrollable chills, profuse sweats and headaches that felt like "a 9-inch spike through my head," he says. The experimental vaccine protected only one of the six volunteers in the trial. Even after drugs quelled the infection, Ballou felt run-down for weeks.

But that lone success provided inspiration for a far more potent malaria vaccine ...
[How on earth did someone arrive at the conclusion that the sixth person was protected by the vaccine?
Why was the malaria case (Ballou's) not made mild by the vaccine?
How many meningitis cases are caused by vaccines?
If we are living a more healthy lifestyle and have "better medicine", then why do we have emerging diseases (below)?] ...

Mayo Clinic vaccine researcher Gregory Poland counts more than a dozen new diseases that have emerged in the last few decades: HIV, Lyme disease, West Nile virus, avian influenza. The vaccine boom, he says, "is shaking up the market."

The $13 billion global vaccine business will grow 18% a year to $30 billion in 2011, predicts Lehman Brothers (nyse: LEH - news - people ), well above the 4.4% annual growth expected for the drug industry overall. Merck (nyse: MRK - news - people ) introduced three new vaccines last year, including Gardasil to ward off cervical cancer, while GlaxoSmithkline promises seven over the next five years, including a Gardasil competitor now awaiting approval from the Food & Drug Administration. AstraZeneca (nyse: AZN - news - people ) bought vaccinemaker MedImmune for $15.6 billion in June, while Pfizer (nyse: PFE - news - people ) last fall bought PowderMed, a British firm testing a needle-free inoculation. Sanofi-Aventis (nyse: SNY - news - people ) spent $150 million for a new plant that will double its flu shot production capacity in the United States to 100 million doses.

A new adult and adolescent vaccine market will make up a big portion of that growth. Diseases such as antibiotic-resistant hospital infections and genital herpes have become hot targets. One company, VaxInnate, is testing a universal flu vaccine that would work against all strains and wouldn't have to be taken every year. ...

Source/Read more: